Enorama Pharma sues FDA over refuse-to-file decision on PMTA applications

• Enorama Pharma is pursuing litigation in the U.S. District Court for the District of Columbia over the FDA’s refusal-to-file decision on its PMTA submissions.
• The FDA completed its reconsideration, upheld the original refusal-to-file decision, leaving the company’s court challenge as the active route.
• The case targets procedural aspects of the FDA decision, seeking judicial review rather than a merits ruling on the applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608141000BITN____UKPR__SV_20260814-BIT-8025-0) on August 14, 2026, and is solely responsible for the information contained therein.